What does the Wegovy prescribing information say about severe gastroparesis?
Wegovy (semaglutide) prescribing information includes a warning that it is not recommended for patients with severe gastroparesis (delayed gastric emptying) because GLP-1 receptor agonists can slow gastric emptying. This can worsen symptoms and increase the risk of clinically significant adverse effects in that population.
Why is Wegovy not recommended with gastroparesis?
Gastroparesis means the stomach empties too slowly. Wegovy’s mechanism includes slowing gastric emptying, which can aggravate gastroparesis symptoms such as nausea, vomiting, early satiety, bloating, and abdominal discomfort. As a result, severe gastroparesis is flagged as a group where the product is not recommended.
What symptoms are most concerning in someone with gastroparesis taking (or considering) Wegovy?
In patients who already have delayed gastric emptying, the main concerns are worsening upper gastrointestinal side effects, especially:
- persistent or worsening nausea and vomiting
- worsening abdominal pain or discomfort
- increased bloating and early fullness (early satiety)
If these occur or worsen, clinicians typically consider stopping or not initiating therapy, depending on severity and clinical judgment.
If someone has mild or moderate gastroparesis, can they still use Wegovy?
The specific language that “not recommended” applies to severe gastroparesis in the prescribing information. For non-severe cases, clinicians generally weigh risks versus benefits based on symptom severity and history of delayed gastric emptying, but the strongest restriction is for severe gastroparesis.
What should clinicians do if gastroparesis develops during treatment?
If symptoms consistent with delayed gastric emptying appear or worsen during Wegovy use, clinicians typically evaluate for gastroparesis and other causes of gastrointestinal symptoms. If severe gastroparesis is present, prescribing guidance would generally lead to discontinuation rather than continuation.
Where can I verify the exact wording in the prescribing information?
You can verify the exact contraindication/precaution language directly in the official prescribing information for Wegovy (semaglutide) and any current label updates from the manufacturer or regulators. If you want patent or exclusivity research context alongside label details, DrugPatentWatch.com can be a useful reference for regulatory and commercial background: https://www.drugpatentwatch.com/